Website Beta Testing – Insite Website Design Sat, 15 Jan 2022 07:08:36 +0000 en-US hourly 1 Website Beta Testing – Insite Website Design 32 32 Starting January 19, will provide free rapid tests Sat, 15 Jan 2022 07:00:22 +0000

As condom sales decline, world’s largest condom company plans to start manufacturing medical gloves

The world’s largest condom manufacturer has not been spared by the coronavirus epidemic as consumption of its product has fallen by 40% in two years.

Contraception use has not increased as individuals have stayed home to prevent transmission of the virus, according to Karex Bhd CEO Goh Miah Kiat.

During the outbreak, hotels and non-essential clinics like sexual wellness centers closed and governments suspended condom distribution programs, Goh told Nikkei Asia.

The Malaysian company produces one in five condoms in the world, for a total of about 5.5 billion each year. It manufactures condoms for Durex as well as its own line of flavored condoms.

Given the often overcrowded residences of the Third World, hotels and motels provide vital private sex venues, according to Goh.

Hotels have been closed during the lockdowns and condom use in the sex industry has dropped significantly over the past two years.

Western governments have also stopped distributing condoms. “Governments around the world distribute a large portion (of condoms),” he added.

“In the UK, the NHS has closed most non-essential clinics due to COVID, and condom dispensing clinics have also been closed.”

Amid global lockdowns forcing people to stay indoors, Karex predicted double-digit growth in condom consumption.

But it is now entering the lucrative medical glove market, with plans to start production in Thailand by mid-year.

Goh said Karex will start with two production lines and 500 million pieces per year, eventually expanding to ten lines and 2.5 billion pieces. Goh said condoms and gloves are made from the same materials and technologies, but gloves have a lower barrier of entry.

World’s fastest carbon-neutral blockchain launched Thu, 13 Jan 2022 08:52:01 +0000

PARIS, January 13, 2022 (GLOBE NEWSWIRE) – Archethic, the world’s fastest and most secure blockchain network, has launched the Archaeological Laboratory Web portal, offering a series of tools that make it easier for users and developers to join the growing ecosystem of the project.

The website contains links to the Archethic website test network and mainnet beta, regular video technology updates, plus all the tools and documentation a newcomer will need to get started.

“We embrace the spirit of scalable community-led initiatives with an open invitation to developers looking for an exciting blockchain project to get involved in from the start,” said Sebastien dupont, President, Archéthique Foundation. “This initiative is led by Web3 builders for Web3 builders. With Archethic’s highly scalable blockchain perfectly prepared for actual use in high traffic use cases such as content publishing (or website hosting), messaging solutions, we are very happy to see This project will evolve as crypto and blockchain are finally being adopted into the mainstream.

Test how to safely store $ UCO in the Archéthique mobile wallet

One of the tools that will be useful to anyone interested in supporting the project (not just the developers) is the Archethic mobile wallet. The wallet supports Archethic $ UCO tokens transactions and is also compatible with NFT transfers on Archethic’s testnet.

A GitHub page is available with APKs to download a mobile wallet on Android devices. The page also includes a repository for developers to build their own portfolios and a beta of a web application portfolio.

The wallet is highly secure, with no loss of funds if the wallet is deleted from a device. A 24-word mnemonic recovery password is all you need to re-access the wallet on any compatible device. Users should make sure to keep their securely saved recovery password in offline or analog format for maximum security.

Create a one page website (any website), explore the network and more

The other three tools are for developers who want to start building on the Archéthic blockchain. In all cases, comprehensive documentation has been provided – usually in written and video form – to facilitate learning the ropes.

AEWeb is a tool that helps web developers deploy websites on the blockchain. Boasting a decentralized security layer comparable to aviation security standards, Archethic is the first choice for deploying a website as secure as possible against hackers and all other possible security failures.

There are many websites being created around the world every day. However, 99% of them are very small to medium sized sites, with very high maintenance costs and security risks. AEWeb provides a one-stop solution to all of these problems at a fraction of the total cost. In addition, it is simple to use, saves a lot of time and is secure.

Tag strings

the Tag Explorer is a blockchain explorer that examines the “beacon chains” used to coordinate and synchronize the Archéthique network. Archethic uses a unique consensus protocol called ARCH that runs multiple grouped tag chains in parallel, each chain being made up of blocks each containing a single committed transaction. The ARCH consensus protocol is what allows Archethic to operate at lightning speed, capable of processing up to 1 million transactions per second.

Testnet faucet

Finally, developers looking to create DApps that interface with UCO will need a way to test their projects. The Archéthic testnet is equipped with a UCO faucet which provides 100 UCO at a time, strictly for testing purposes. This allows developers to create projects without spending their own funds to validate code. Being a naturally eco-friendly blockchain, Archethic is also profitable, and the UCO faucet is yet another step towards saving resources of all kinds.

The beta of Archethic mainnet launched in June 2021 after four years of research and development aimed at resolving the limitations and challenges faced by other blockchains. The project aims to disrupt traditional industries such as retail and finance, giving interested developers plenty of opportunities to create innovative new technologies with the potential to have real impact.

On Archethical public blockchain

Archethics is a highly scalable and tamper-proof Blockchain with scalability over 1 million TPS and validation time under 5 seconds. The blockchain has the capacity to handle up to 90% malware, 3.6 billion times less power consumption than Bitcoin, and 0.1% transaction fees.

The platform aims to replace and enhance all current applications with a complete and open ecosystem, enabling people to move from the trust imposed by centralized systems to decentralized systems while keeping identity and privacy under control. of the user.

With Archethic, you can access your identity but no one has it. The security and threat challenges posed by centralized systems have helped us realize that sovereign identity is needed more than ever. An autonomous and decentralized Open Source network in the hands of the world population created by the people, for the people. ??

Official Archetic Links


White paper:







Media contact

Whatsapp Android Beta: voice notes will soon be playable in the background Tue, 11 Jan 2022 14:20:00 +0000

WhatsApp has reportedly added a voice notes feature for its upcoming Android beta update.

According to reports, the first time the platform introduced this feature was in April 2021, when the speed of playing voice notes was discussed. In September of the same year, the app made it possible to preview the notes before sending them to another user.

This time around, the social media app probably introduces another change for this feature. In the future, users will be able to listen to their voicemail messages in the background.

New global WhatsApp voice note reader

(Photo: Alexander Shatov from Unsplash)
WhatsApp has reportedly added a voice notes feature for its upcoming Android beta update.

According to a report by XDA Developers, WABetaInfo revealed that the most recent Android beta will now allow a user to play voice notes in the background.

At the top of the app, users will notice that the voice notes player will appear after you finish playing the voice notes and entering the home / chat screen.

Users will also see its progress bar next to its buttons which you can use to resume, pause, and close voice notes. Apart from that, WhatsApp may allow to resume voice note reader after opening another app. There is no official confirmation of this change at the time of publication.

WABetaInfo wrote that this feature is currently under development, so expect it not to be available right away, even for beta users. By the way, the report gives a glimpse of what it can offer in the future.

More details on this feature are not yet revealed on the official site. WhatsApp has yet to give an exact date for its launch on the app’s beta channel.

Related article: WhatsApp’s New Feature Identifies Nearby Businesses! Gradual rollout for iOS already underway

WhatsApp “Mentions” feature

In another Daily Star report, WhatsApp is said to be developing a new feature that can notify you if your friends are chatting to you on the app. If you’re curious about what people are saying about you when you’re not around, this is one feature you can’t afford to miss.

According to the article, WhatsApp may eventually roll out a feature that will mention your name in group chats you belong to. To add, it will be more manageable on your end since you can easily respond to someone in your circle.

Before, there will be a message alert that will notify you if someone leaves a message. This time the sender’s profile picture will appear as a notification. This will immediately notify the user talking about it without experiencing the need to scroll endlessly.

Currently, iOS 15 beta testers are testing this feature. WhatsApp has not yet announced the date of its availability on the Android platform.

Other features of WhatsApp

Last month, Tech Times announced that WhatsApp will now prevent users from seeing the “last seen” status of other people they don’t know. It’s part of the app’s privacy plan to prevent strangers from stalking users they haven’t chatted with before.

In the same month, we also wrote an article on the app’s new pilot cryptocurrency payment feature that will be available in the United States. This would now allow consumers to send and receive money from family, friends and others through the app.

Also Read: WhatsApp Crackdown: Users Logging In With Unofficial App Versions Could Face Permaban | How to fix this?

This article is the property of Tech Times

Written by Joseph Henry

2021 All rights reserved. Do not reproduce without permission.

Beam Therapeutics reports progress on Ex Vivo and In Sun, 09 Jan 2022 14:00:00 +0000

First subject scheduled to be enrolled in the BEAM-101 phase 1/2 clinical trial for the treatment of sickle cell anemia in the second half of 2022

BEAM-301 named fourth development candidate for treatment of glycogen storage disease type Ia

Appointment of two additional development candidates scheduled for 2022

Company to provide updates on its 40-year pipeline and operationse JP Morgan Healthcare Annual Conference January 10, 2022 at 2:15 p.m. ET

CAMBRIDGE, Mass., Jan. 9, 2022 (GLOBE NEWSWIRE) – Beam Therapeutics Inc. (Nasdaq: BEAM), a biotech company that develops precision genetic drugs through core publishing, today outlined planned milestones for 2022 in its ex vivo programs targeting the editing of hematopoietic stem cells (HSC) and T cells and in vivo programs targeting liver cell editing using lipid nanoparticles (LNP) for delivery. Updates include that the company has selected its fourth development candidate and its first in vivo Basic edition candidate, BEAM-301, which aims to correct the R83C mutation for the potential treatment of patients with glycogen storage disorder Ia (GSDIa).

“We made significant progress across our core publishing portfolio in 2021, which resulted in the approval by the United States Food and Drug Administration of the first application of a new investigational drug. of a basic editing process, BEAM-101. We have also extended our platform, in particular with delivery of LNP from basic editors to the liver and our proprietary technology to accelerate delivery of LNP to other tissues, including HSCs, ”said John Evans, CEO of Beam. “We believe 2022 will be our most important year yet, with preparations underway to launch the BEACON-101 clinical trial with BEAM-101 for the treatment of sickle cell anemia and to complete our transition to becoming a stage company. clinical. We believe we are well positioned today, with four development candidates, a rich pipeline of early stage programs, and a platform of cutting-edge publishing and delivery technologies enabling us to deliver a new class of genetic drugs from precision. None of this would be possible without the commitment of our remarkable team of intrepid innovators. We look forward to the year ahead and continue our work to bring life-changing drugs to as many patients as possible. “

Ex vivo HSC programs

  • BEAM-101 is an experimental autologous, patient-specific HSC therapy that incorporates core modifications designed to mimic the single nucleotide polymorphisms seen in people with inherited fetal hemoglobin persistence. BEAM-101 aims to potentially attenuate the effects of mutations causing sickle cell disease (SCD) or beta thalassemia by causing an increase in fetal hemoglobin, which inhibits the polymerization of hemoglobin S (HbS). The BEACON-101 trial is a phase 1/2 clinical trial designed to evaluate the safety and efficacy of BEAM-101 for the treatment of sickle cell anemia. The trial should include an initial “sentinel” cohort of three patients, treated one at a time to confirm successful engraftment, followed by administration to a total of 45 patients. Beam has started the site selection and institutional review board approval processes for the BEACON-101 trial and plans to enroll the first subject in the second half of 2022.
  • BEAM-102 is designed to treat SCD by directly modifying the causal HbS point mutation to recreate a naturally occurring variant of normal human hemoglobin, HbG-Makassar. The Makassar variant has been reported to have the same function as the more common HbA variant and does not cause SCD. Beam plans to submit an Investigational New Drug (IND) application for BEAM-102 in the second half of 2022.

Ex vivo T cell programs

  • BEAM-201 is an investigational multiplex-based anti-CD7 CAR-T therapy designed to treat relapsed / refractory acute lymphoblastic T-cell leukemia, a serious disease affecting children and adults. Beam plans to submit an IND application for BEAM-201 in the second half of 2022.
  • Beam plans to appoint a second CAR-T development candidate in 2022.

In Vivo LNP liver targeting programs

  • BEAM-301, the company’s newest development candidate, is a liver-targeting LNP formulation of basic editing reagents designed to correct the R83C mutation. R83C is the most common pathogenic mutation in GSDIa, a life-changing genetic disease for which no approved disease-modifying therapy is available today. Beam plans to launch studies enabling IND for BEAM-301 in 2022.
  • Beam plans to appoint a second developmental candidate targeting the liver in 2022.

JP Morgan Healthcare Conference
Mr. Evans will present updates to Beam’s pipeline and activities in a presentation at 40e JP Morgan Healthcare Annual Conference on Monday, January 10, 2022 at 2:15 p.m. ET. A live webcast will be available in the investors section of the Company’s website at and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading fully integrated platform for precision genetic drugs. To realize this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of developing in-house manufacturing capabilities. Beam’s suite of gene-editing technologies is anchored in base editing, a proprietary technology that enables precise, predictable and efficient simple base changes at the level of targeted genomic sequences without making double-stranded breaks in DNA. This enables a wide range of potential therapeutic editing strategies that Beam uses to advance a diverse portfolio of core editing programs. Beam is a values-driven organization committed to its people, cutting-edge science and a vision to provide lifelong treatment to patients with serious illnesses.

Caution regarding forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on such forward-looking statements, including, but not limited to, statements relating to: our plans, and expected timeline, to nominate additional development candidates, initiate studies enabling IND and submit IND applications; the therapeutic applications and the potential of our technology, in particular with regard to sickle cell anemia, beta-thalassemia, T-ALL, GSDIa and LNP; the planned launch and design of our BEACON-101 clinical trial, including the timeline for enrollment of the first subject in the trial; our presentations planned at a future conference; and our ability to develop precision, curative, and permanent genetic drugs for patients through core editing. Each forward-looking statement is subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties relating to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than anticipated; our ability to raise additional funds, which may not be available; our ability to obtain, maintain and enforce patents and other intellectual property protections for our product candidates; the potential impact of the COVID-19 pandemic; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or future clinical trials; that recruiting for our clinical trials may take longer than expected; that our product candidates may experience interruptions or failures in manufacturing or supply; risks associated with competing products; and other risks and uncertainties identified under the headings “Summary of Risk Factors” and “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2020, our quarterly report on Form 10-Q for the quarter ended March 31, 2021, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and in any subsequent filing with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to vary may occur from time to time, and we cannot predict all of them. We assume no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable law.


Chelcie Lister
THRUST Strategic Communication

Dan Budwick

Source link

FDA shortens interval for Moderna’s Covid-19 booster dose to 5 months Sat, 08 Jan 2022 01:21:00 +0000
Dr Rochelle Walensky, director of the US Centers for Disease Control and Prevention, speaks with CBS Mornings on Friday, January 7, 2022 (CBS)

Dr Rochelle Walensky, director of the US Centers for Disease Control and Prevention, told CBS Mornings on Friday that the CDC had not focused its recommendations around isolating Covid-19, but instead provided guidance to those who chose to have an antigen test.

“I remind you that isolation is for people who have tested positive,” she said, when asked about changes to isolation guidelines. “We now have dozens of articles that are now on our CDC website that we have reviewed to update these guidelines in the context of the science and epidemiology of our time.”

She said it is known that for one to two days before infection and two to three days after symptoms, this is the time when a person is most infectious. By the fifth day, after the symptoms, “most of that contagiousness, that contagiousness is really behind you,” she said.

“This is really where they say: do you have symptoms? If your symptoms improve, it’s safe to go out as long as you wear a mask all the time, ”she said. “What we heard over the past week is that a lot of people were interested in using an antigen test, they had access to the antigen test.”

“So we didn’t pivot our recommendations, what we did was provide advice on how you would use and interpret this antigen test, if you so chose to take a measurement. extra to get one, ”she said. “And that is, if it’s positive, stay home. And if it is negative, please continue to wear your mask, because that does not mean that you are no longer contagious. ”

When asked if testing would be required before leaving isolation if testing was widely available and access was not an issue, Walensky said “we need testing to leave quarantine – quarantine being that period of time after being exposed. What I’m saying is that we need to provide guidance that is, you know, science-based, grounded in the epidemiology of our present time, and applicable at the state and local jurisdiction level. ”

“If they can’t get a test, they should wear a mask,” Walensky said, when asked what people who haven’t been able to take a test should do after the five days of isolation. . “And that’s actually really what our tips say, isolate for those first five days, after those first five days, make sure you feel better, if you feel better then you can really go out, but you have to. go out and you have to wear your mask all the time.

Walensky also responded to criticism of the release of the guidelines, saying that “we are working 24/7, 12,000 people to keep America safe, to update our guidelines in the context of a very rapidly evolving science and a very rapidly evolving epidemiology. We have room, we can improve our communications on how we deliver this science to the American people. We will continue to do so. We have received criticism, but we have also received a number of approvals of these new directions. ”

Source link

Consumer Reports Confirms Tesla Model S Has Driver Watching Feature Thu, 06 Jan 2022 00:20:00 +0000 On December 24, we reported a discrepancy between what Consumer Reports wrote about Tesla’s Driver Surveillance Camera and what Tesla said on its website. While the consumer organization said the Model S has this system, Tesla has advised (and still does) that only the Model 3 and Y feature it. Jake Fisher reached out to us to show that Tesla updates their cars faster than taking care of their website.

The senior manager of CR’s automatic test center sent us an image of the Model S digital owner’s manual. In it, Tesla informs this:

“Cabin camera

Model S is equipped with a cab camera located above the mirror (-).

The cab camera can determine driver inattention and provide you with audible alerts to remind you to keep your eyes on the road when autopilot is engaged. By default, camera images and videos do not leave the vehicle itself and are not transmitted to anyone, including Tesla, unless you enable data sharing.

Despite what the VE The manufacturer’s website still says the driver watch feature is exclusive to Model 3 and Model Y, Tesla’s website is out of date. It’s unclear which update gave the electric sedan that ability, but the point is that it can try to avoid distracted driving – at least in theory.

CR really tested FSD in a vehicle that could check whether the driver is paying attention to the road or not. What the consumer organization realized was that hiding the internal camera did not disengage FSD: it continued to function as if nothing had happened. Concretely, it is as if the camera did not exist or did not have this function, as Tesla still says.

More than an issue with the driver monitoring system – which also failed to reduce driver distraction in CR’s Model Y – this episode shows A V experts are right to urge US authorities to take action on FSD.

Besides the erratic behavior beta software exhibits on public roads in the hands of regular drivers, knowing that it stays active even when drivers are not careful is a major issue. Many Tesla owners believe FSD makes their cars self-sufficient and continue to try to prove it in YouTube videos with risky attitudes like sleeping or playing video games.

Now dispelled from all doubt, CR’s warning is just another drop in a sea of ​​demands for the proper application of autonomous vehicle test procedures. NHTSA seems to be taking them more seriously lately – and it should. A business that updates its cars faster than updating its customers’ information requires tighter guidance.

Source link

Latest news on the COVID-19 epidemic on Monday, January 3 Tue, 04 Jan 2022 02:15:00 +0000

1:17 p.m. – Declaration of the Ministry of Health

Almost 4,500 recalls were administered yesterday (4,494), a jump of over 1,500 the day before.

This increase serves as a timely reminder that from tomorrow (Wednesday, January 5), the interval between the second doses and the boosters goes from six months to four months.

This means that anyone aged 18 and over who received their second vaccination at least four months ago can receive their booster dose.

COVID-19 tests have also increased in the past 24 hours, with around 1,000 more tests administered than the day before.

Omicron update

We are now declaring 29 cases identified at the border. Pending full genome sequencing of these cases, some of these cases are expected to be the Omicron variant.

This variant of COVID-19 continues to have a significant impact globally, so it’s no surprise to see an increase in cases identified at the border.

COVID-19 vaccine update

  • Vaccines administered to date (percentage of eligible persons): 3,975,528 first doses (94%); 3,856,703 second doses (92%); 29,226 third primary doses; 333,820 recalls
  • Vaccines administered yesterday: 363 first doses; 1306 seconds; 25 third primary doses and 4,494 booster doses.
  • Maori (percentage of eligible people): 500,643 first doses (88%); 462,192 second doses (81%)
  • Peoples of the Pacific (percentage of those eligible): 271,432 first doses (95%); 259,464 second doses (91%)

DHB vaccination rate with active cases (percentage of eligible people)

  • Northland DHB: first doses (89%); second doses (84%)
  • Auckland Metro DHB: first doses (96%); second doses (94%)
  • Waikato DHB: first doses (94%); second doses (90%)
  • Bay of Plenty DHB: first doses (93%); second doses (90%)
  • DHB lakes: first doses (92%); second doses (88%)
  • Taranaki DHB: first doses (93%); second doses (89%)
  • Tairāwhiti DHB: first doses (91%); second doses (86%)
  • Hawke’s Bay DHB: first doses (95%); second dose (91%)
  • Canterbury DHB: first doses (98%); second doses (95%)


Hospital cases: 53; North Shore: 9; Auckland: 16; Middlemore: 22; Tauranga: 5 Rotorua: 1

Vaccination status of current hospitalizations (services in the North region only): Not vaccinated or not eligible (20 cases / 46.5%); partially immune less than 7 days after the second dose or having received only one dose (8 cases / 18.6%); fully vaccinated at least 7 days before being reported as a case (14 cases / 32.6%); 1 unknown (2.3%).

Average age of current hospitalizations: 53 years

ICU or HDU cases: 6 (3 in Middlemore; 3 in Tauranga)


  • Seven-day moving average of community cases: 43.4
  • Number of new community cases: 31
  • Number of new cases identified at the border: 29
  • Location of new community cases: Auckland (14), Waikato (1), Bay of Plenty (12), Lakes (4)
  • Number of community cases (total): 10,985 (in current community outbreak)
  • Epidemiologically related cases (total): 8,268
  • Number of active cases (total): 1,143 (cases identified in the last 21 days and not yet classified as cured)
  • Confirmed cases (total): 13,992


  • Number of active contacts managed (total): 5,426
  • Percentage of people who received an outgoing call from contact tracers (to confirm testing and isolation requirements): 83%
  • Percentage that returned at least one result: 78%


  • Total number of tests (last 24 hours): 8,661
  • Running average of tests (last 7 days): 11,148
  • Auckland tests total (last 24 hours): 3,956


No unexpected detection

1:07 p.m. – The Ministry of Health reports a third case linked to the border with the Omicron variant.

The case is a family contact of the Air New Zealand crew member who tested positive last week with the Omicron variant.

Family contact was isolated during its symptomatic period. Public health staff continue to investigate, but at this point there are no places of interest or exhibition events.

Family contact has now been transferred to an MIQ facility. The second family contact, which is also isolated, continues to be negative.

The case is fully vaccinated.

1:00 p.m. – There are 31 new cases of COVID-19 in the community on Tuesday. Fifty-three people are hospitalized, sic in intensive care and there are 29 cases at the border that are being tested to see if they are Omicron.

12:40 – Another new variant of COVID-19 with dozens of mutations has been discovered, this time in France.

The IHU, as it has been dubbed, has the N501Y mutation also found in Alpha, Beta, Omicron, and Gamma variants, which makes it more contagious, and the E484K mutation found in Gamma and Beta, which helps the virus escape. to people’s immunity, as well as many other changes.

It was found in around ten patients living in Forcalquier, in the south of France. The index case was a man who had recently traveled to Cameroon, southern Africa, which – like much of the region – has incredibly low vaccine coverage, which facilitates the emergence of variants.

Read the full story here

12:20 – New South Wales continues to see the number of cases soar with another 23,131 confirmed cases in the state on Tuesday. Two more deaths from COVID-19 have also been reported along with a record 1,344 people hospitalized.

Source link

How do I register for the Super People beta testing program? Sat, 01 Jan 2022 10:44:19 +0000

How do I register for the Super People beta testing program? Wonder People is working on a royal fighting game called Super People. This is a battle royale game that features overpowered individuals as the unique selling factor. As the game progresses, players will be able to gain more power. They will eventually have access to special powers and ultimate abilities that will allow them to change the course of a battle. Players will be able to collect materials throughout a Super People battle. These materials can then be used to craft high-end weapons and other equipment.

Extended closed beta testing for super people

Wonder People, a game development studio, has said beta testing of the Super People “Battle Royale” will be extended indefinitely. According to them, this was done because the project received a lot of positive feedback from players and there is a chance to collect more suggestions and feedback on errors. The creators are now working on solving rendering and loading difficulties, optimizing the game, balancing weapons and classes, and increasing server reliability.

Also Read: Vandal vs Phantom: Which Weapon Among These Pros Like Tenz, Scream, Shroud & Asuna Prefer

How do I register for the Super People beta testing program? Super People planned release date

How do I register for the Super People beta testing program? Super People planned release date

How to register for the closed beta test

To participate in the Super People beta, head over to the game’s Steam page and request access, or head over to the official Wonder People website and sign up for the beta. According to their website, adding the game to your Steam wishlist increases your chances of being chosen.

  • Go to your Steam account and sign in.
  • To find Super People in the app, use the search box.
  • Locate and tap the huge green Request Access button.
  • Enter your information after verifying it.

However, many players suffer from “Process delayed” authorization issues due to a large number of incoming requests. Please try again in 5 minutes “

Super People planned release date

Since the game recently completed a beta phase, the content of the game or the way players access it may change in the future based on feedback received by Wonder People. The developers of Super People haven’t given a definitive release date, but the game is slated for Q1 2022.

Read More – Top 10 Most Anticipated Games For Year 2022 You Should Keep Your Eyes On

– Advertising –

Source link

Shiba Inu could increase dramatically early next year Fri, 31 Dec 2021 14:07:00 +0000

As of 2017, there is always a general sale of cryptocurrencies at this time of year. This counts for Bitcoin and all other altcoins and tokens. This mainly has to do with taxes, as many traders and investors plan to reap tax losses just before the end of the fiscal year.

The sharp price drop we’re seeing with Shiba Inu is likely related to the sale of cryptos at the end of the year for tax reasons. Like every year, we expect almost all cryptocurrencies, including Shiba Inu, to bounce back and resume their upward momentum. At the time of writing, Shiba Inu was trading at 0.00003427 $, with an 11% drop over the past week. Currencies like Dogecoin have also fallen significantly this week.

Another new crypto cited as the next Shiba inu by analysts due to its breakthrough tokenomics is making big strides this week. EverGrow (EGC) crypto, launched in September 2021, is considered the fastest growing cryptocurrency of its kind, automatically rewarding holders with 8% of every Binance Pegged USD ($ BUSD) transaction. According to BSCscan, the crypto launched 12 weeks ago is already over 119K token holders. With the team’s recent announcement regarding the beta launch of utilities including the NFT lending platform, content subscription platform, and play-to-earn games, crypto could experience a big uplift. .

Considering the price of the Shiba Inu, when we factor in on-chain metrics, we find that 54% of all SHIB holders are currently in the money and 78% of all Shiba Inu token holders should be considered. like great holders. Depending on the composition of holders by length of detention, 87% of them hold between 1 and 12 months. So what we can conclude is that the selling we are seeing right now is just a matter of seasonal trading and the bulls will most likely start showing up in early 2022 or when Shib drops even lower to buy. additional tokens at a reduced price.

It should not be forgotten either that by Shiba Inu market capitalization, although being a huge $ 17.25 billion in size, is much smaller than the Ethereum or Bitcoin market cap. This means that Shiba Inu is more likely to have higher volatility, which could explain why we have seen Shiba Inu lose so much value over the past two weeks. For Shiba Inu bulls, the bright spot here is that the upside potential is also much greater, and those who invest in Shiba Inu can expect a higher return on their investment than other (major) altcoin bulls.

Turning to today’s SHIB trading, we are already seeing Shiba Inu gearing up for a big ascent as it nears a significant resistance line at $ 0.00003902. If Shib could find solid support at this level, we can expect a rise of over 40%, testing it high of November 30 of $ 0.00005435.

Although there will most likely be bumps in the road at his 50 day SMA of $ 0.00004099, for example, enough buying pressure could easily break this and send Shiba Inu to the top, from 2022 into the green for most SHIB investors and traders.

Solana, The next potential Ethereum, achieved growth of over 45,000% in 2021. Solana’s blockchain technology means faster and cheaper transactions, and this project poses a direct threat to Ethereum.

Although has a late 2022 price prediction of only $ 200 For Solana (a 15% return from current levels), many analysts can see Solana closing the gap with Ethereum, the world’s second largest cryptocurrency by market cap. This could mean over 700% returns for Solana in 2022 to achieve their lofty ambitions. Subscribe to the News Reportz newsletter and update on the latest crypto trends.

Company: News Reportz

E-mail: [email protected]

SOURCE News Reportz

Source link

Aderant partners with LawPay to integrate fully automated online payment solutions for clients Aderant Expert Practice Management Wed, 29 Dec 2021 14:01:00 +0000

Expert and Expert Sierra Integration with LawPay will be released in 2022

ATLANTA, December 29, 2021– (BUSINESS WIRE) – Aderant®, a leading global provider of business management software, announced a new partnership with LawPay, the leading accounts receivable solution for law firms in North American markets. Many Adderant Expert and Expert Sierra clients accept online payments through ClientPay, which combined with LawPay in February 2021 to form the industry-leading payment solution for large law firms. The Expert / LawPay integration, slated for release in 2022, will fully automate and extend payment activation options for Expert / Sierra customers to include a fully cloud-based payment solution with scheduled payments, encrypted signatures, online payments and more.

LawPay, an AffiniPay solution, is used by more than 50,000 law firms in North America. On average, law firms that accept payments online using LawPay receive payments 39% faster. Adderant’s integration with LawPay will benefit law firms and their clients, making it easier for them to pay their firms quickly thanks to LawPay’s secure cloud-based technology that streamlines the payment process. Businesses can send invoices to customers with a secure link so that customers can instantly pay their invoices on the company’s website, by email, or even from mobile devices.

“We are delighted to partner with LawPay as their robust offering ensures that customers are paid easily, securely and most importantly, quickly,” said Rafi Shure, COO at Aderant. “We look forward to completing our integration work so that our expert clients can reap even more benefits from their collaboration with Aderant and LawPay. “

Aderant’s technology is state-of-the-art and integrating its Expert and Expert Sierra law firm management software with LawPay’s leading online payment platform into a fully automated system is a great next step in effectively serving law firms and their clients, ”said Meg Swanson, Marketing Director, LawPay. “We are working closely with Aderant to create a seamless integration between Expert and LawPay so that Aderant customers can start using it with a significant advantage in 2022.”

For more information on Aderant Expert, please visit: To join the Expert / LawPay Integration Beta Test Group, send an email to

About Aderant®
Aderant is a global industry leader providing comprehensive business management software for law firms and other professional service organizations. The company’s popular technology brands include Aderant Expert / Expert Sierra for practice management, Handshake and Drive for knowledge management, iTimekeep, OCG Live & Thrive for timing and compliance, BillBlast for electronic invoicing, CompuLaw for registration and agenda, and Expert Case for the management of legal affairs. . Aderant operates as a unit of Roper Technologies (NYSE: ROP), a component of the S&P 500 ®, Fortune 500 ® and the Russell 1000 ® clues. The company is headquartered in Atlanta, Georgia, and has several other offices in North America, Europe, and Asia-Pacific. For more information visit, email or follow the company on Twitter @Aderant or LinkedIn.

About LawPay
LawPay was developed specifically to help law firms streamline billing and collections, providing a simple and secure solution for legal clients to pay their bills. LawPay is the industry leader in legal payments, providing a cost effective solution to over 50,000 law firms across the country. It is available at all 50 state bars, over 60 local and specialty bars, and ABA as a verified and approved payment solution for the legal industry. LawPay is also ALA’s exclusive VIP payment processing partner. Learn more at

See the source version on


Megan Haight
Director, Channel Marketing, Aderant

Christy Burke, Burke & Company RP

Keely Leonard
Public Relations Manager, LawPay

Source link